Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and peripheral blood mononuclear cells

被引：0
|
作者：
Voortman, J. [1 ]
Ceresa, C. [2 ]
Giovannetti, E. [1 ]
Laan, A. C. [1 ]
Honeywell, R. [1 ]
Giaccone, G. [3 ]
Peters, G. J. [1 ]
机构：
[1] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[2] Univ Milano Bicocca, Monza, Italy
[3] NCI, Bethesda, MD 20892 USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：34 / 34
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetics and pharmacogenetics of gemcitabine combined with epirubicin or cisplatin in non-small cell lung cancer patients
    Maring, JG
    Wachters, FM
    Slijfer, M
    Maurer, M
    Uges, DRA
    de Vries, EGE
    Groen, HJM
    THERAPEUTIC DRUG MONITORING, 2005, 27 (02) : 234 - 235
  • [22] Plasma pharmacokinetics and excretion in saliva of epirubicin and gemcitabine in patients with non-small cell lung cancer
    Maring, JG
    Wachters, FM
    Maurer, JM
    Dodde, IW
    Groen, HJM
    Uges, DRA
    De Vries, EGE
    THERAPEUTIC DRUG MONITORING, 2003, 25 (04) : 532 - 532
  • [23] Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study
    Zhihong Ma
    Hongwei Li
    Bin Wang
    Qibin Shen
    Enhai Cui
    Lishan Min
    Fuchu Qian
    Jinliang Ping
    Licheng Dai
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 557 - 562
  • [24] Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study
    Ma, Zhihong
    Li, Hongwei
    Wang, Bin
    Shen, Qibin
    Cui, Enhai
    Min, Lishan
    Qian, Fuchu
    Ping, Jinliang
    Dai, Licheng
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (04) : 557 - 562
  • [25] A novel dosing schedule with gemcitabine, vinorelbine, and carboplatin for advanced non-small cell cancer of the lung.
    Sadasivan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 708S - 708S
  • [26] Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib
    Cheng, Hua
    An, She-Juan
    Dong, Song
    Zhang, Yi-Fang
    Zhang, Xu-Chao
    Chen, Zhi-Hong
    Jian-Su
    Wu, Yi-Long
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2011, 4
  • [27] A tolerance and pharmacodynamics pharmacokinetics study with modified 3 weeks regimen of Gemcitabine Plus Cisplatin in advanced Non-Small Cell Lung Cancer patients
    Fan Yun
    Lin Ming N
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S678 - S678
  • [28] Gemcitabine and radiation therapy for non-small cell lung cancer
    Vokes, EE
    Gregor, A
    Turrisi, AT
    SEMINARS IN ONCOLOGY, 1998, 25 (04) : 66 - 69
  • [29] Gemcitabine and paclitaxel combinations in non-small cell lung cancer
    Dombernowsky, P
    Giaccone, G
    Sandler, A
    Schwartsmann, G
    SEMINARS IN ONCOLOGY, 1998, 25 (04) : 44 - 50
  • [30] Gemcitabine/carboplatin in advanced non-small cell lung cancer
    Zatloukal, P
    Petruzelka, L
    LUNG CANCER, 2002, 38 : S33 - S36
12345